Tetracyclines as a potential antiviral therapy against Crimean Congo hemorrhagic fever virus: Docking and molecular dynamic studies

Sharifi, Amirhossein; Amanlou, Arash; Moosavi-Movahedi, Faezeh; Golestanian, Sahand; Amanlou, Massoud

doi:10.1016/j.compbiolchem.2017.06.003

Cited by 15 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Doxycycline showed inhibition of entry and replication of Chikungunya virus in Vero cell at 11 µM [23]. Using the in-silico method, doxycycline might be a potential inhibitor of Crimean-Congo hemorrhagic fever virus nucleoprotein, an essential protein in virus replication [24]. Additionally, doxycycline inhibited the early-stage replication of the porcine reproductive and respiratory syndrome virus, which causes respiratory disease, with EC 50 (median effective concentration) of 0.25 µg/mL (about 0.5 µM) [25].…”

Section: Introductionmentioning

confidence: 99%

In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2

et al. 2020

View full text Add to dashboard Cite

In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), emerged in Wuhan, China. Despite containment measures, SARS-CoV-2 spread in Asia, Southern Europe, then in America and currently in Africa. Identifying effective antiviral drugs is urgently needed. An efficient approach to drug discovery is to evaluate whether existing approved drugs can be efficient against SARS-CoV-2. Doxycycline, which is a second-generation tetracycline with broad-spectrum antimicrobial, antimalarial and anti-inflammatory activities, showed in vitro activity on Vero E6 cells infected with a clinically isolated SARS-CoV-2 strain (IHUMI-3) with median effective concentration (EC50) of 4.5 ± 2.9 µM, compatible with oral uptake and intravenous administrations. Doxycycline interacted both on SARS-CoV-2 entry and in replication after virus entry. Besides its in vitro antiviral activity against SARS-CoV-2, doxycycline has anti-inflammatory effects by decreasing the expression of various pro-inflammatory cytokines and could prevent co-infections and superinfections due to broad-spectrum antimicrobial activity. Therefore, doxycycline could be a potential partner of COVID-19 therapies. However, these results must be taken with caution regarding the potential use in SARS-CoV-2-infected patients: it is difficult to translate in vitro study results to actual clinical treatment in patients. In vivo evaluation in animal experimental models is required to confirm the antiviral effects of doxycycline on SARS-CoV-2 and more trials of high-risk patients with moderate to severe COVID-19 infections must be initiated.

show abstract

Section: Introductionmentioning

confidence: 99%

In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Favipiravir is a broad-spectrum RNA inhibitor that has shown promising results 41. Tetracyclines, cationic amphiphilic drugs and ubiquitin variants are under investigation as potential antiviral therapies42–44; however, none are in clinical-stage development.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic tests for Crimean-Congo haemorrhagic fever: a widespread tickborne disease

Mazzola

Kelly-Cirino

2019

BMJ Glob Health

View full text Add to dashboard Cite

Crimean-Congo haemorrhagic fever (CCHF) is a widespread tickborne disease that circulates in wild and domestic animal hosts, and causes severe and often fatal haemorrhagic fever in infected humans. Due to the lack of treatment options or vaccines, and a high fatality rate, CCHF virus (CCHFV) is considered a high-priority pathogen according to the WHO R&D Blueprint. Several commercial reverse transcriptase PCR (RT-PCR) and serological diagnostic assays for CCHFV are already available, including febrile agent panels to distinguish CCHFV from other viral haemorrhagic fever agents; however, the majority of international laboratories use inhouse assays. As CCHFV has numerous amplifying animal hosts, a cross-sectoral ‘One Health’ approach to outbreak prevention is recommended to enhance notifications and enable early warning for genetic and epidemiological shifts in the human, animal and tick populations. However, a lack of guidance for surveillance in animals, harmonisation of case identification and validated serodiagnostic kits for animal testing hinders efforts to strengthen surveillance systems. Additionally, as RT-PCR tests tend to be lineage-specific for regional circulating strains, there is a need for pan-lineage sensitive diagnostics. Adaptation of existing tests to point-of-care molecular diagnostic platforms that can be implemented in clinic or field-based settings would be of value given the potential for CCHFV outbreaks in remote or low-resource areas. Finally, improved access to clinical specimens for validation of diagnostics would help to accelerate development of new tests. These gaps should be addressed by updated target product profiles for CCHFV diagnostics.

show abstract

“…Crimean-Congo hemorrhagic fever virus is a member of a family of hemorrhagic fever viruses, and its nucleoprotein is a key protein in virus replication. Min and Dox can inhibit this protein, slowing viral replication [ 60 ].…”

Section: Tetracyclines As Antiviral Agentsmentioning

confidence: 99%

Tetracycline and viruses: a possible treatment for COVID-19?

Mosquera-Sulbarán

Hernández–Fonseca

2020

Arch Virol

View full text Add to dashboard Cite

Tetracyclines have been used to treat many bacterial infections. The use of these antibiotics for the treatment of viral diseases dates to the 1960s to 1970s. Over the decades, the effect of tetracyclines on the pathogenesis of viral infections has been demonstrated both clinically and experimentally. Tetracyclines can act on viral infections either through their antibacterial properties or through direct antiviral action. This review focuses on clinical and experimental data that support the use of tetracycline in treating viral infections and highlights an important approach to slowing disease progression during viral infections. Tetracycline treatment might represent a strategy for eliminating the infection or inhibiting the progression of COVID-19.

show abstract

Tetracyclines as a potential antiviral therapy against Crimean Congo hemorrhagic fever virus: Docking and molecular dynamic studies

Cited by 15 publications

References 30 publications

In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2

In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2

Diagnostic tests for Crimean-Congo haemorrhagic fever: a widespread tickborne disease

Tetracycline and viruses: a possible treatment for COVID-19?

Contact Info

Product

Resources

About